ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.322,59
0,91%
S&P 500
5.969,34
0,35%
Dow Jones
44.296,51
0,97%
Euro vs US Dollar
1,0418
0,00%
Bitcoin
98.243,15
0,47%
Pepperstone
Advertisement
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Sonnet BioTherapeutics Holdings Inc (SONN)

  7. Sonnet BioTherapeutics Holdings Inc (SONN) News

SONN

Sonnet BioTherapeutics (SONN)

Sonnet BioTherapeutics Holdings Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:SONN
DatumZeitQuelleÜberschriftSymbolFirma
12/11/202415h15GlobeNewswire Inc.Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” SegmentNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
08/11/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
07/11/202415h22Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
07/11/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
06/11/202419h20GlobeNewswire Inc.Sonnet BioTherapeutics Announces Pricing of $5.0 Million Underwritten Public Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
06/11/202415h22Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
06/11/202414h48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
06/11/202414h30GlobeNewswire Inc.Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug CandidatesNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
04/11/202415h01Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
28/10/202414h01Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
17/10/202414h50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
17/10/202414h45GlobeNewswire Inc.Sonnet BioTherapeutics Inc. Regains Compliance with NasdaqNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
09/10/202414h56Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
09/10/202414h45GlobeNewswire Inc.Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in IndiaNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
04/10/202414h30GlobeNewswire Inc.Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive ProgramsNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
30/09/202415h00GlobeNewswire Inc.Sonnet BioTherapeutics Announces Launch of CEO Corner PlatformNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
30/09/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
25/09/202414h30GlobeNewswire Inc.Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock SplitNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
18/09/202414h36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
18/09/202414h30GlobeNewswire Inc.Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid TumorsNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
12/09/202423h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
09/09/202422h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
04/09/202415h15GlobeNewswire Inc.Sonnet BioTherapeutics to Participate in the Virtual Investor Closing Bell SeriesNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
30/08/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
19/08/202423h28Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
19/08/202423h27Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
19/08/202414h50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
19/08/202414h45GlobeNewswire Inc.Sonnet BioTherapeutics Enters into Clinical Collaboration Agreement to Commence Investigator-Initiated and Funded Phase 1/2a Study of SON-1210 in Combination with Chemotherapy for the Treatment of Pancreatic CancerNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
14/08/202414h45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SONNSonnet BioTherapeutics Holdings Inc
14/08/202414h41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SONNSonnet BioTherapeutics Holdings Inc
 Showing the most relevant articles for your search:NASDAQ:SONN

Kürzlich von Ihnen besucht

BIT
UB891L
Unicredit Bank
TG
GU81
Aviva
BIT
UC45ZJ
Unicredit Bank
BIT
UB30EA
UniCredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten